Neurogene Inc (NGNE)vsRevolution Medicines Inc (RVMD)
NGNE
Neurogene Inc
$26.49
-3.60%
HEALTHCARE · Cap: $418.59M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. NGNE earns a higher WallStSmart Score of 31/100 (F).
NGNE
Avoid31
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NGNE
The strongest argument for NGNE centers on Debt/Equity, Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NGNE
The primary concerns for NGNE are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
NGNE carries more volatility with a beta of 2.04 — expect wider price swings.
NGNE is growing revenue faster at 0.0% — sustainability is the question.
NGNE generates stronger free cash flow (-26M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NGNE scores higher overall (31/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurogene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical needs in the field of genetic medicine. The company boasts a promising and proprietary pipeline, showcasing its commitment to harnessing cutting-edge technologies for transformative treatment solutions. With a seasoned leadership team guiding its strategic direction, Neurogene is poised to make substantial contributions to the advancement of genetic therapies, ultimately enhancing the quality of life for patients and their families impacted by these challenging conditions. As Neurogene progresses through critical clinical development phases, it stands as a key player in the evolving landscape of genetic therapeutics.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?